119 related articles for article (PubMed ID: 29559616)
1. The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.
Huang S; Jiang C; Zhang H; Bell T; Guo H; Liu Y; Yao Y; Zeng D; Ahmed M; Nomie K; Zhang L; Wang M
Blood Cancer J; 2018 Mar; 8(3):33. PubMed ID: 29559616
[No Abstract] [Full Text] [Related]
2. Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma.
Kuroda Y; Yashima-Abo A; Koyama D; Kikuchi J; Mori S; Ito S; Furukawa Y
Leukemia; 2021 May; 35(5):1506-1510. PubMed ID: 32929128
[No Abstract] [Full Text] [Related]
3. Orbital mantle cell lymphoma presenting as myasthenia gravis.
Karlin J; Peck T; Prenshaw K; Portell CA; Kirzhner M
Orbit; 2017 Dec; 36(6):365-369. PubMed ID: 28820310
[TBL] [Abstract][Full Text] [Related]
4. Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells.
Polito L; Mercatelli D; Bortolotti M; Maiello S; Djemil A; Battelli MG; Bolognesi A
Toxins (Basel); 2017 May; 9(6):. PubMed ID: 28556822
[TBL] [Abstract][Full Text] [Related]
5. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
6. Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.
Tran L; Huitema AD; Vogel WV; Beijnen JH; Baars JW
J Oncol Pharm Pract; 2012 Dec; 18(4):417-20. PubMed ID: 22228555
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
8. A novel strategy for engineering of a smart generation of immune ribonucleases against EGFR
Taghizadegan N; Firoozrai M; Nassiri M; Ariannejad H
J Cell Physiol; 2021 Jun; 236(6):4303-4312. PubMed ID: 33421131
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
10. Novel Nanoscale Delivery Particles Encapsulated with Anticancer Drugs, All-trans Retinoic Acid or Curcumin, Enhance Apoptosis in Lymphoma Cells Predominantly Expressing CD20 Antigen.
Stauffer RG; Mohammad M; Singh AT
Anticancer Res; 2015 Dec; 35(12):6425-9. PubMed ID: 26637852
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
12. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
13. Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1-positive cell lines.
Forouharmehr A; Nassiri M; Ghovvati Roudsari S; Javadmanesh A
J Cell Physiol; 2020 May; 235(5):4679-4687. PubMed ID: 31663127
[TBL] [Abstract][Full Text] [Related]
14. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
16. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
[TBL] [Abstract][Full Text] [Related]
17. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
18. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines.
Visco C; Castegnaro S; Chieregato K; Bernardi M; Albiero E; Zanon C; Madeo D; Rodeghiero F
Blood Cells Mol Dis; 2012 Jan; 48(1):68-75. PubMed ID: 22036761
[TBL] [Abstract][Full Text] [Related]
19. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial.
Furtado M; Dyer MJ; Johnson R; Berrow M; Rule S
Br J Haematol; 2014 May; 165(4):575-8. PubMed ID: 24666179
[No Abstract] [Full Text] [Related]
20. Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes.
Zarei N; Fazeli M; Mohammadi M; Nejatollahi F
Breast Cancer Res Treat; 2018 Jun; 169(3):427-436. PubMed ID: 29411237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
